Cas:4402-83-9 methyl 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carboxylate manufacturer & supplier

Chemical Name:methyl 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carboxylate

CAS.NO:4402-83-9

Synonyms:3-<2,6-Dichlor-phenyl>-5-methyl-isoxazol-4-carbonsaeure-methylester;methyl 3-(2,6-dichlorophenyl)-5-methylisoxazole-4-carboxylate;3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylcarboxylic Acid Methyl Ester;3-(2,6-Dichlorophenyl)-5-methylisoxazole-4-carboxylic acid methyl ester;3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxylic acid,methyl ester

Molecular Formula:C₁₂H₉Cl₂NO₃

Molecular Weight:286.11100

HS Code:2934999090

Physical and Chemical Properties:

Melting point:115ºC

Boiling point:382.4ºC at 760 mmHg

Density:1.37 g/cm3

Index of Refraction:1.561

PSA:52.33000

Exact Mass:284.99600

LogP:3.74340

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-&lt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxylic acid,methyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylcarboxylic Acid Methyl Ester Use and application,3-&lt technical grade,usp/ep/jp grade.

Related News: Brian McNamara, currently head of GSK’s consumer healthcare division, will continue to serve as the franchise’s CEO after it breaks away from GSK in 2022, the British pharma said Thursday. 1-[4-(4-Nitro-benzenesulfonyl)-phenylamino]-propan-2-one manufacturers Such investment is by no means prohibitive and can reap substantial rewards that include shorter development timelines, lower costs, faster time to market, and game changing technological advantage for sustainable competitive edge. (2R,3R)-3-Benzyloxy-2-(3,4-dimethoxy-phenyl)-7-methoxy-chroman suppliers Soliris would need a “substantial discount” to reach a more appropriate price, according to its report. Using the widely leveraged measure for disease burden known as quality-adjusted life year (QALY), ICER calculated a range of $6,900 to achieve $50,000 per QALY to $25,700 to hit $200,000 per QALY. 2-methyl-7-nitro-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid ethyl ester vendor & factory.